Search the RE article base
Contact Information
Twitter
My TweetsUseful Web Sites
Author Archives: Gerald Barnett
10 Ways Universities Deal in Patents
I have been thinking about how university technology transfer is depicted, versus how it actually happens. The depictions are something of a prophetic hope–inventions reported to the university’s licensing office will be evaluated for “commercial potential” and those that look … Continue reading
Posted in Patents, Technology Transfer
Tagged nothing ever happens, patents
Comments Off on 10 Ways Universities Deal in Patents
Bayh-Dole, Federal Agency Conflict of Interest, and the Covid Vaccines
Here is a recent video clip of an interview with Robert F. Kennedy, Jr. He asserts that it was known that HCQ and Ivermectin were effective in treating corona viruses by 2004. Robert F. Kennedy Jr. claims that "We knew … Continue reading
Faculty Strategies for Getting Their IP Back, 2
Here are some strategies for getting IP back that don’t work or avoid IP ownership. (1) Don’t disclose an invention to the university, and file for a patent on your own. Your application will be published in a year or … Continue reading
Faculty Strategies for Getting Their IP Back
If you are a faculty member at an American university, you will get a lot of twisted advice from your university technology transfer office about intellectual property, Bayh-Dole, and patent policy. The advice (and descriptions about technology transfer) is mostly … Continue reading
Posted in Bozonet, Policy, Technology Transfer
Tagged conditional, faculty, startup
Comments Off on Faculty Strategies for Getting Their IP Back
AUTM arguments for not complying with Bayh-Dole
Just a quick note here on AUTM arguments are for not complying with Bayh-Dole. Just off a meeting that paid attention to AUTM’s position. I’ll summarize the main arguments here. Access in the form of commercial products is more important … Continue reading
Posted in Bayh-Dole, Policy
Tagged B.S., Bayh-Dole, reasonable use
Comments Off on AUTM arguments for not complying with Bayh-Dole
Government Funding For Research, 1
Out in Twitterland, I saw this tweet by Brett Blackham: Arguably, research and development is so important that government should have nothing to do with it. However since 1980 a company or university could get government money to do research … Continue reading
Posted in Bad Science, Innovation, Sponsored Research
Tagged government funding, research
Comments Off on Government Funding For Research, 1
Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in
The American Prospect has an interesting piece (“A Big Miss on Drug Prices”) on the NIH yet again defying the Bayh-Dole Act and refusing to launch an investigation into whether UCLA and Pfizer have met Bayh-Dole’s standard (35 USC 201(f)) … Continue reading
Posted in Bayh-Dole
Tagged administration agreement, Bayh-Dole, march-in, patent rights clause, Xtandi
Comments Off on Xtandi, Bayh-Dole, and how Pfizer might stop worrying and love the march in
Inventors would own more, were it not for noncompliant Bayh-Dole practice
I saw this tweet this morning: I agree Inventors should own more, but institutions were/are the heart of Bayh-Dole that (arguably) enables IP-driven startups… this is bc many/most PI inventions would go into a black hole without tech transfer officer … Continue reading
Why not let’s try, Frank?
Frank Cullen, writing at the “Council for Innovation Promotion” has posted a hand-wringing response to a letter from members of Congress to the Secretary of Health and Human Services requesting that the government use Bayh-Dole’s march-in provisions to address price … Continue reading
March-in rights, Xtandi, and Bayh-Dole’s patent rights clause
Senator Bernie Sanders just tweeted about Xtandi, asking patients taking Xtandi to share their stories. The prostate cancer drug Xtandi was invented by taxpayer-funded scientists at UCLA, but now costs Americans nearly $190,000 — or up to six times the … Continue reading
Posted in Bayh-Dole, high priced drugs
Tagged Bayh-Dole, competition, march-in, reasonable terms, Xtandi
Comments Off on March-in rights, Xtandi, and Bayh-Dole’s patent rights clause